ijms-logo

Journal Browser

Journal Browser

Special Issue "Skin Cancer: State-of-the-Art"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 31 October 2021.

Special Issue Editors

Prof. Dr. Andrzej Mackiewicz
E-Mail Website
Guest Editor
1. Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan 61-866, Poland
2. Greater Poland Cancer Centre, Poznan, Poland
Interests: melanoma; cancer; skin; skin cancer; DNA repair
Prof. Dr. Piotr Rutkowski
E-Mail Website
Co-Guest Editor
Head of Department of Soft Tissue/Bone Sarcoma and Melanoma ; Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy Warszawa / Maria Sklodowska-Curie National Research Institute of Oncology
Interests: skin cancer; melanoma; Soft Tissue Sarcoma; Bone Sarcoma; Keratoma;

Special Issue Information

Dear colleagues,

Skin cancers are the most common malignancies in Caucasians and the most mutated human cancers. Among them, melanoma has been widely used by scientists as a model for cancer research. Its primary lesion is mostly located in the skin. However, about 14% arises in eyes. Some, even in meninges. The melanoma researchers discovered, explored and better understood multiple mechanisms involved in carcinogenesis, tumor microenvironment, tumor-patient interactions and, finally, novel treatment modalities. Moreover, the developments in pathogenesis of skin carcinomas (basal cell carcinoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma and so on) lead to the introduction of new therapies such as hedgehog inhibitors.

 

In the Special Issue, we would like to publish original skin cancers research, which affected or may affect on the other cancer types in the future. The basic, translational, therapeutic and combination approaches are recommended. Review papers summarizing earlier discoveries such as molecular targets for diagnosis and/or treatment of melanoma and cutaneous carcinomas, which are used in other cancers, immunotargets and immunotherapy such as cancer vaccines, immune check-points inhibitors, cancer stem cells, including further perspectives for developments. Meta-analyzes of big-data generally available (such as The Cancer Genome Atlas) for further validation in experimental settings are also welcome.

Prof. Dr. Andrzej Mackiewicz

Prof. Dr. Piotr Rutkowski

Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Melanoma
  • Skin
  • Eyes
  • Meninges
  • Basic
  • Translational
  • The Cancer Genome Atlas
  • Meta-analyses

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies
Int. J. Mol. Sci. 2021, 22(12), 6305; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22126305 - 11 Jun 2021
Cited by 1 | Viewed by 1048
Abstract
Merkel cell carcinoma (MCC) is an uncommon and highly aggressive skin cancer. It develops mostly within chronically sun-exposed areas of the skin. MCPyV is detected in 60–80% of MCC cases as integrated within the genome and is considered a major risk factor for [...] Read more.
Merkel cell carcinoma (MCC) is an uncommon and highly aggressive skin cancer. It develops mostly within chronically sun-exposed areas of the skin. MCPyV is detected in 60–80% of MCC cases as integrated within the genome and is considered a major risk factor for MCC. Viral negative MCCs have a high mutation burden with a UV damage signature. Aberrations occur in RB1, TP53, and NOTCH genes as well as in the PI3K-AKT-mTOR pathway. MCC is highly immunogenic, but MCC cells are known to evade the host’s immune response. Despite the characteristic immunohistological profile of MCC, the diagnosis is challenging, and it should be confirmed by an experienced pathologist. Sentinel lymph node biopsy is considered the most reliable staging tool to identify subclinical nodal disease. Subclinical node metastases are present in about 30–50% of patients with primary MCC. The basis of MCC treatment is surgical excision. MCC is highly radiosensitive. It becomes chemoresistant within a few months. MCC is prone to recurrence. The outcomes in patients with metastatic disease are poor, with a historical 5-year survival of 13.5%. The median progression-free survival is 3–5 months, and the median overall survival is ten months. Currently, immunotherapy has become a standard of care first-line therapy for advanced MCC. Full article
(This article belongs to the Special Issue Skin Cancer: State-of-the-Art)
Show Figures

Figure 1

Review
Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation
Int. J. Mol. Sci. 2021, 22(10), 5077; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22105077 - 11 May 2021
Viewed by 767
Abstract
Adnexal tumors of the skin are a rare group of benign and malignant neoplasms that exhibit morphological differentiation toward one or more of the adnexal epithelium types present in normal skin. Tumors deriving from apocrine or eccrine glands are highly heterogeneous and represent [...] Read more.
Adnexal tumors of the skin are a rare group of benign and malignant neoplasms that exhibit morphological differentiation toward one or more of the adnexal epithelium types present in normal skin. Tumors deriving from apocrine or eccrine glands are highly heterogeneous and represent various histological entities. Macroscopic and dermatoscopic features of these tumors are unspecific; therefore, a specialized pathological examination is required to correctly diagnose patients. Limited treatment guidelines of adnexal tumor cases are available; thus, therapy is still challenging. Patients should be referred to high-volume skin cancer centers to receive an appropriate multidisciplinary treatment, affecting their outcome. The purpose of this review is to summarize currently available data on pathogenesis, diagnosis, and treatment approach for apocrine and eccrine tumors. Full article
(This article belongs to the Special Issue Skin Cancer: State-of-the-Art)
Show Figures

Figure 1

Review
Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Follicular Differentiation
Int. J. Mol. Sci. 2021, 22(9), 4759; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22094759 - 30 Apr 2021
Viewed by 745
Abstract
Neoplasms derived from follicular tissue are extremely rare. Clinically, they are reported as non-symptomatic, slow-growing nodules. These lesions are mainly benign, but the malignant type can occur. Mainly middle-aged people (50–60 years of age) are affected. These carcinomas are mainly localized on the [...] Read more.
Neoplasms derived from follicular tissue are extremely rare. Clinically, they are reported as non-symptomatic, slow-growing nodules. These lesions are mainly benign, but the malignant type can occur. Mainly middle-aged people (50–60 years of age) are affected. These carcinomas are mainly localized on the head and neck or torso. They can be locally aggressive and infiltrate surrounding tissue and metastasize to regional lymph nodes. In the minority of cases, distant metastases are diagnosed. Quick and relevant diagnosis is the basis of a treatment for all types of tumors. The patient’s life expectancy depends on multiple prognostic factors, including the primary tumor size and its mitotic count. Patients should be referred to a specialized skin cancer center to receive optimal multidisciplinary treatment. This article tries to summarize all the information that is currently available about pathogenesis, diagnosis, and treatment methods of follicular tumors. Full article
(This article belongs to the Special Issue Skin Cancer: State-of-the-Art)
Show Figures

Figure 1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Multicenter population-based study of the long-term efficacy of vismodegib in treatment of patients with advanced basal cell carcinoma.
Authors: Monika Dudzisz-Śledź 
Affiliation: Maria Sklodowska-Curie National Research Institute of Oncology

Title: Dermoscopy of micro-melanomas and the diagnostic feasibility of selected algorithms – clinical retrospective multicenter study.
Authors: Mateusz Spalek 
Affiliation: Maria Sklodowska-Curie National Research Institute of Oncology

Title: Results of Merkel cell carcinoma treatment - multicenter study.
Authors: Anna Małgorzata Czarnecka 
Affiliation: Maria Sklodowska-Curie National Research Institute of Oncology

Title: Current diagnosis and treatment options for cutaneous adnexal carcinomas with apocrine and eccrine differentiation.
Authors: Monika Slowinska
Affiliation: Maria Sklodowska-Curie National Research Institute of Oncology

Title: Current diagnosis and treatment options for cutaneous adnexal carcinomas with follicular differentiation.
Authors: Anna Szumera-Ciećkiewicz 
Affiliation: Maria Sklodowska-Curie National Research Institute of Oncology

Title: {a review on mucosal melanomas focusing on molecular features and state of the art of systemic and combination treatments}
Authors: Mario Mandalà
Affiliation: Università di Perugia, Italy

Back to TopTop